Edwards Lifesciences Q4 Earnings Fall Short Of Expectations, Reaffirms FY22 Outlook

Loading...
Loading...

Heart device company Edwards Lifesciences Corp EW posted Q4 adjusted EPS of $0.51, compared to $0.50 posted a year ago and below the consensus of $0.55.

  • Sales for Q4 increased 12% to $1.33 billion (underlying 13%), missing the consensus of $1.36 billion.
  • Transcatheter aortic valve replacement (TAVR) sales grew to $872 million, up 12% despite the “pronounced impact on hospital resources” in December from the omicron variant of COVID-19, said CEO Mike Mussallem. 
  • The Company cited the delta variant wave in third-quarter results.
  • TAVR sales outside the U.S. grew about 20% on an underlying basis in Q4, and Edwards Lifesciences said it continues to project that the global TAVR opportunity will double to $10 billion by 2028.
  • In Q4, R&D expenses grew 19% to $233 million, primarily on transcatheter innovations such as increased transcatheter mitral and tricuspid therapies (TMTT) clinical trial activity. 
  • Guidance: Edwards Lifesciences reaffirmed its FY22 projection of adjusted EPS of $2.50 - $2.65 and reiterated its top-line outlook of $5.5 billion to $6.0 billion.
  • For Q1 FY22, Edwards Lifesciences expects revenue between $1.27 billion - $1.35 billion and adjusted EPS of $0.54 to $0.62.
  • Analyst Reaction: SVB Leerink maintains Edwards Lifesciences with an Outperform but lowered the price target from $132 to $130.
  • Price Action: EW shares are down 5.27% at $102.91 during the premarket session on the last check Thursday.
Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...